HAO vs MCHX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HAO presents as a classic value trap, characterized by a stable Piotroski F-Score of 6/9 and a Graham Number of $13.09 that vastly exceeds the current price of $1.07. While valuation metrics like the P/E (0.84) and Price/Book (0.18) suggest extreme undervaluation, these are offset by a catastrophic YoY revenue decline of 64.60%. The disconnect between a positive net profit margin (11.82%) and a negative operating margin (-21.16%) suggests that earnings are likely driven by non-operating items rather than core business health. Combined with a 0/100 technical trend and long-term price collapse, the fundamental business decay outweighs the theoretical value.
MCHX exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness in operational efficiency and financial health. Despite a clean balance sheet with very low debt (D/E 0.02) and adequate liquidity, the company is struggling with negative revenue growth (-9% YoY) and consistent net losses. The forward P/E of 149.00 suggests an extremely poor earnings outlook, and the technical trend is fully bearish. While one analyst maintains a high target price of $4.00, the fundamental data does not support such a valuation.
Compare Another Pair
Related Comparisons
HAO vs MCHX: Head-to-Head Comparison
This page compares Haoxi Health Technology Limited (HAO) and Marchex, Inc. (MCHX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.